West Pharmaceutical Services, Inc. Stock News

The price of West Pharmaceutical Services plunged over 38% after it released its Q4 and FY 2024 earnings results on February 13. Shareholders, mostly institutional investors apparently, did not like the bottom-line results nor the uninspiring guidance for 2025. Still, West should not be overlooked, and there may be opportunities if the share price continues to rebound after a market overreaction.

West Pharmaceutical Services, a global provider of solutions for drugs, biologics, gene therapies, and consumer healthcare products, recently announced its Q4 results, surpassing analysts' expectations for both revenue and earnings. The company reported sales of $749 million and adjusted earnings per share of $1.82, compared to $740 million and $1.73, respectively.

West Pharmaceutical Services, Inc. (NYSE:WST ) Q4 2024 Earnings Conference Call February 13, 2025 9:00 AM ET Company Participants John Sweeney - Vice President of Investor Relations Eric Green - Chairman, President & Chief Executive Officer Bernard Birkett - Senior Vice President & Chief Financial Officer Conference Call Participants Michael Ryskin - BofA Global Research Lawrence Solow - CJS Se...

West Pharmaceutical Services Inc.'s stock tumbled 33% Thursday, to lead S&P 500 decliners, after the manufacturer of injectable-pharmaceutical packaging and delivery systems offered guidance for 2025 that was well below expectations.

West Pharmaceutical Services fails to impress with a weak 2025 outlook.

West Pharmaceutical Services forecast full-year profit and revenue below Wall Street estimates on Thursday due to a strong dollar and as the medical equipment maker's clients reduce inventory levels, sending its shares down 18% premarket.

- Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa.

EXTON, Pa. , Jan. 30, 2025  /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST),  global leader in innovative solutions for injectable drug administration, today announced that it will release fourth-quarter and full-year 2024 financial results before the market opens on Thursday, February 13, 2025, and will follow with a conference call to discuss the results and business expectatio...